COVID-19 | Infectious Disease | NIH | Vaccine
Investigational AstraZeneca vaccine prevented COVID-19
On Mar. 22, 2021, the National Institutes of Health (NIH) announced that results from a large clinical trial…
-
-
US, Chile and Peru interim trial data showed Oxford-AstraZeneca vaccine was safe and highly effective
On Mar. 22, 2021, Oxford University announced that a Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted…
-
AIM ImmunoTech announced addition of single-agent Ampligen arm to Cancer Center’s study in cancer patients with COVID-19
On Mar. 22, 2021, AIM ImmunoTech announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer…
-
Moderna announced supply agreement with the Philippines for 7 million additional doses of COVID-19 Vaccine Moderna
On Mar. 22, 2021, Moderna announced that the Philippines had secured 7 million additional doses of COVID-19 Vaccine…
-
Phase III data showed investigational antibody cocktail reduced hospitalisation or death in patients with COVID-19
On Mar. 22, 2021, Roche confirmed positive topline results from the largest trial to date assessing a COVID-19…
-
Cepheid received Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test
On Mar. 21, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
-
FDA authorized first machine learning-based screening device to identify COVID-19 infection biomarkers
On Mar. 19, 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the…
-
Existing vaccines may protect against the Brazilian coronavirus variant
On Mar. 19, 2021, scientists at the University of Oxford released pre-print data measuring the level of antibodies…
-
UK and EU regulatory agencies confirmed COVID-19 Vaccine AstraZeneca was safe and effective
On Mar. 18, 2021, AstraZeneca announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines…
-
XPhyto announces European approval for 25 minute COVID-19 PCR test
On Mar. 18, 2021, XPhyto and its exclusive German diagnostics development partner, 3a-diagnostics, are pleased to announce the…
-
Incyte announced results from phase 3 DEVENT study evaluating Jakafi as treatment for patients with COVID-19
On Mar. 18, 2021, Incyte announced results from the Phase 3 DEVENT study evaluating the efficacy and safety of…
-
FDA permitted marketing of first SARS-CoV-2 diagnostic test using traditional premarket review process
On Mar. 17, 2021, the U.S. Food and Drug Administration (FDA) granted marketing authorization of the BioFire Respiratory…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science History | Therapeutics | Vaccine
Altasciences partnered with NRC of Canada to qualify quantitative serological assay for detection of SARS-CoV-2 IgG antibodies
On Mar. 17, 2021, Altasciences working with the National Research Council of Canada (NRC), announced that it had…
-
WHO COVID-19 subcommittee announced safety signals related to AstraZeneca COVID-19 vaccine
On Mar. 17, 2021, the World Health Organization (WHO) reported that the AstraZeneca COVID-19 vaccine (including Covishield) continued…
-
Research highlighted risks of separating newborns from mothers during COVID-19 pandemic
On Mar. 16, 2021, research from the World Health Organization (WHO) and partners showed that the COVID-19 pandemic…
-
TGen study predicted changing Lyme disease habitat across the West Coast
On Mar. 16, 2021, TGen announced a study that suggested ecosystems suitable for harboring ticks that carry debilitating…
-
Moderna announced participants dosed in phase 2/3 study of COVID-19 vaccine in pediatric population
On Mar. 16, 2021, Moderna announced that the first participants had been dosed in the Phase 2/3 study,…
-
Biotechnology | CDC | COVID-19 | Diagnostics | Genomics | Infectious Disease | Vaccine
Fulgent Genetics awarded contract from CDC to study variants of COVID-19 virus
On Mar. 15, 2021, Fulgent Genetics announced that the U.S. Centers for Disease Control and Prevention had awarded…
-
ImmunityBio announced positive interim phase I safety data of hAd5 T-cell COVID-19 vaccine candidate
On Mar. 15, 2021, ImmunityBio announced it had met the safety requirements for the first 12 participants in…
-
First participants dosed in Moderna phase 1 study evaluating mRNA-1283 next generation COVID-19 vaccine
On Mar. 15, 2021, Moderna announced that the first participants had been dosed in the Phase 1 study…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine | WHO
WHO added Janssen vaccine to list of safe and effective emergency tools against COVID-19
On Mar. 12, 2021, The World Health Organization (WHO) listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson…
-
Abbott announced Pandemic Defense Coalition to help prevent future pandemics
On Mar. 11, 2021, Abbott announced the formation of the Abbott Pandemic Defense Coalition, a first-of-its-kind global scientific…
-
Rigel announced completion of patient enrollment for phase 2 trial of fostamatinib in hospitalized COVID-19 patients
On Mar. 11, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to…
-
ImmunityBio announced novel ACE2 decoy COVID-19 therapeutic that showed high binding to SARS-CoV-2 variants
On Mar. 11, 2021, ImmunityBio announced it was developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize…
-
Altimmune expanded AdCOVID manufacturing collaboration with Lonza
On Mar. 11, 2021, Altimmune announced that it had expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the…
-
Novavax confirmed ligh levels of efficacy against original and variant COVID-19 strains in UK and South Africa trials
On Mar. 11, 2021, Novavax announced final efficacy of 96.4% against mild, moderate and severe disease caused by…
-
Johnson & Johnson announced single-shot COVID-19 vaccine candidate received positive CHMP opinion
On Mar. 11, 2021, Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
Johnson & Johnson single-shot COVID-19 vaccine granted conditional Marketing Authorization by EC
On Mar. 11, 2021, Johnson & Johnson announced that the European Commission (EC) had granted a Conditional Marketing…
-
Real-world evidence confirmed high effectiveness of Pfizer-BioNTech COVID-19 vaccine
On Mar. 11, 2021, the Israel Ministry of Health (MOH), Pfizer and BioNTech announced real-world evidence demonstrating dramatically…
-
ContraFect announced BARDA contract award for up to $868 million for antibiotic-resistant infections
On Mar. 11, 2021, ContraFect announced that it had been awarded a cost-share contract from the Biomedical Advanced…
